Neumora Therapeutics (NMRA) Stock Price, Quote, News & History

Comments

Neumora Therapeutics Inc (NMRA) Stock Price, Quote, News & History

NMRANASDAQ

Trade with Public

$3.14

-0.23-6.96%

At close: Mar 11, 5:00 PM EST

$3.20

-0.17-5.19%

Pre-Market: 4:03 AM EST

OverviewNews Earnings Options Analyst Ratings Insider Trades Short Interest Stock Report

Key Statistics

Open

-

Close

$3.14

Volume / Avg.

0 / 1.66M

Day Range

- - -

52 Wk Range

0.61 - 3.65

Market Cap

$543.80M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

48

Short Interest

7.82%

Days to Cover

5.99

Recent Neumora Therapeutics Inc News

Neumora Therapeutics Stock Jumps, Analyst Sees Upside In Alzheimer's Treatment

William Blair upgrades Neumora after strong Alzheimer's agitation data, sees upside from NMRA-511 and obesity pipeline potential.

Vandana Singh

Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday

Avi Kapoor

Neumora's Alzheimer's Agitation Drug Shows Early Promise

NMRA-511 showed promising results in Phase 1b study for Alzheimer's disease agitation with favorable tolerability and safety profile.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-208.83M

Investing Cash Flow (TTM)

27.08M

Financing Cash Flow (TTM)

33.89M

Free Cash Flow (TTM)

-208.84M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-147.86M

Analyst Trends and Forecast

0

Nov 25

1

Dec 25

1

Jan

1

Feb

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.6

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$382.17M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

4.04

Earnings Yield % (TTM)

-46.82%

Earnings Yield % (FWD)

-37.42%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.78

Company Debt

Total Debt

$19.56M

LT Debt

$19.56M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$129.07M

Debt to Equity

0.15

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

-

Close

$3.14

Volume / Avg.

0 / 1.66M

Day Range

- - -

52 Wk Range

0.61 - 3.65

Market Cap

$543.80M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

48

Short Interest

7.82%

Days to Cover

5.99

About

Sector

Health Care

Industry

Pharmaceuticals

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pip...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Neumora Therapeutics (NMRA) stock?

A

You can purchase shares of Neumora Therapeutics (NASDAQ:NMRA) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Neumora Therapeutics (NMRA) competitors?

A

Other companies in Neumora Therapeutics’s space includes: Atea Pharmaceuticals Inc (NASDAQ:AVIR), Theravance Biopharma Inc (NASDAQ:TBPH), Zevra Therapeutics Inc (NASDAQ:ZVRA), SNDL Inc (NASDAQ:SNDL) and Bioage Labs Inc (NASDAQ:BIOA).

Q

What is the forecast, or price target, for Neumora Therapeutics (NMRA) stock?

A

Neumora Therapeutics has a consensus price target of $8.00.

Q

What is the current price for Neumora Therapeutics (NMRA)?

A

The stock price for Neumora Therapeutics (NASDAQ: NMRA) is $3.2 last updated March 12, 2026 at 4:32 PM EDT.

Q

Does Neumora Therapeutics (NMRA) pay a dividend?

A

There are no upcoming dividends for Neumora Therapeutics.

Q

When is Neumora Therapeutics (NASDAQ:NMRA) reporting earnings?

A

Neumora Therapeutics does not have any upcoming earnings scheduled.

Q

Is Neumora Therapeutics (NMRA) going to split?

A

There is no upcoming split for Neumora Therapeutics.

Q

What sector and industry does Neumora Therapeutics (NMRA) operate in?

A

Neumora Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

People Also Watch

Atea Pharmaceuticals Inc

NASDAQ:AVIR

$6.16

0.97%

Theravance Biopharma Inc

NASDAQ:TBPH

$13.89

%

Zevra Therapeutics Inc

Phathom Pharmaceuticals Inc

NASDAQ:PHAT

$10.18

-0.39%

Aquestive Therapeutics Inc

NASDAQ:AQST

$4.04

0.24%

Esperion Therapeutics Inc

NASDAQ:ESPR

$2.51

1.65%

Key Statistics

Open

-

Close

$3.14

Volume / Avg.

0 / 1.66M

Day Range

- - -

52 Wk Range

0.61 - 3.65

Market Cap

$543.80M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

48

Short Interest

7.82%

Days to Cover

5.99

Recent Neumora Therapeutics Inc News

Neumora Therapeutics Stock Jumps, Analyst Sees Upside In Alzheimer's Treatment

William Blair upgrades Neumora after strong Alzheimer's agitation data, sees upside from NMRA-511 and obesity pipeline potential.

Vandana Singh

Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday

Avi Kapoor

Neumora's Alzheimer's Agitation Drug Shows Early Promise

NMRA-511 showed promising results in Phase 1b study for Alzheimer's disease agitation with favorable tolerability and safety profile.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-208.83M

Investing Cash Flow (TTM)

27.08M

Financing Cash Flow (TTM)

33.89M

Free Cash Flow (TTM)

-208.84M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-147.86M

Analyst Trends and Forecast

0

Nov 25

1

Dec 25

1

Jan

1

Feb

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.6

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$382.17M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

4.04

Earnings Yield % (TTM)

-46.82%

Earnings Yield % (FWD)

-37.42%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.78

Company Debt

Total Debt

$19.56M

LT Debt

$19.56M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$129.07M

Debt to Equity

0.15

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

-

Close

$3.14

Volume / Avg.

0 / 1.66M

Day Range

- - -

52 Wk Range

0.61 - 3.65

Market Cap

$543.80M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

48

Short Interest

7.82%

Days to Cover

5.99

About

Sector

Health Care

Industry

Pharmaceuticals

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pip...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry